SavedAdd your journal

Journals / Cerrahpaşa Tıp Dergisi / 2004 / Cilt: 35 - Sayı: 2

Paraoxonase

Paraoksonaz

Balcı Özlem EKMEKÇİ
Hakan EKMEKÇİ
Orkide DONMA
Pages
78–82
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

PON1's free sulpfhydryl group of cystein-284 is required for PON1's ability to protect LDL against oxidation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background.- Paraoxonase (PON1) is a calcium-dependent esterase that is a component of plasma high density lipoprotein (HDL), and hydrolazes organophosphates (e.g. paraoxon, diazooxon), aromatic carboxylicacid esters and nerve gases.
📊
Key Findings & Data:Paraoxonase protects low density lipprotein (LDL) and HDL from oxidation induced by either copper (Cu) ion, or free radicals.
💡
Conclusion & Impact:PON1's free sulpfhydryl group of cystein-284 is required for PON1's ability to protect LDL against oxidation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background.- Paraoxonase (PON1) is a calcium-dependent esterase that is a component of plasma high density lipoprotein (HDL), and hydrolazes organophosphates (e.g. paraoxon, diazooxon), aromatic carboxylicacid esters and nerve gases. Paraoxonase protects low density lipprotein (LDL) and HDL from oxidation induced by either copper (Cu) ion, or free radicals. This protection is probably related to PON's ability to hydrolyze some oxidized phospholipids and/or cholestryl linoleate hydoperoxidases which are present in Ox-LDL. PON1's free sulpfhydryl group of cystein-284 is required for PON1's ability to protect LDL against oxidation.

Özet

İnsan serum Paraoksonaz (PON1) enzimi; HDL üzerinde lokolize, kalsiyum (Ca) bağımlı bir ester hidrolazdır ve organofosfatları (paraokson, diazookson gibi) sinir ajanlarını ve aromatik karboksilik asit esterlerini hidroliz eder. Ayrıca; LDL ve HDL'yi, Cu iyonunun ve serbest radikallerin indüklediği oksidasyondan koruyarak antioksidan etki gösterir. Paraoksonaz enzimi, okside LDL’de bulunan kolesterol linolat hidroperoksitleri ve/veya okside fosfolipidleri hidroliz ederek bu koruyucu etkisini gösterebilir. Paraoksonaz enzimi sistein 284 pozisyonunda serbest sülfidril grubu içerir ve bu yapı oksidasyona karşı LDL' yi korumada önem taşımaktadır.

🔖

Cite This Article

EKMEKÇİ, B. Ö., EKMEKÇİ, H., DONMA, O. (2022). Paraoxonase. Cerrahpaşa Tıp Dergisi, Cilt: 35 - Sayı: 2, 78–82. https://ajindex.com/articles/473479

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Abbot CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity,concentrations and phenotype distribution in diabetes mellitus its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Bio. 1995; 15: 1812-18
  2. Heijmans BT, Westendorp RGJ, Lagaay AM, Knook DL, Kluft C, Slagboom PE. Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis, 2000; 149: 91-7
  3. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordon-Starck TJ, Harmony JAK. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 1994; 33: 832-39
  4. Hasselwander O, McMaster D, Fogarty AD, Maxwell AP, Nicholls DP, Young JS. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin Chem 1998; 44: 179-82
  5. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol.1997; 17: 1233-38
  6. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem, 1986; 32: 671-3
  7. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D, Rosenblat M. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions. Circulation 2000; 101: 2510-17
  8. Garin MCB, Abbot C, Messmer S, Mackness M, Durrington P, Pometta D, James RW. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J 1994; 304: 549-54
  9. La Du BN, Aviram M, Billecke S, Navab M. On the physical role(s) of the paraoxonases. Chem -Biol Inter 1999; 119-120: 379-88
  10. Mackness B, Durrington PN, Mackness MI. Human serum Paraoxonase. Gen Pharm 1998; 3: 329-36
  11. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001; 21: 473-80
  12. Rye KA, Clay MA, Barter PJ. Remodelling of high- density lipoproteins by plasma factors. Atherosclerosis 1999; 145: 227-238
  13. Heinecke JW. Eosinophil-dependent bromination in the pathogenesis of asthma. J Clin Invest, 2000; 105: 1331-2
  14. Aviram M, Rosenblat M, Scott B, Erogul J, Sorenson R, Bisgaier CI, Newton RS, La Du B. Human serum paraoxonase (PON 1) is inactivat